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Membrane transporters may determine drug ADME properties 
Kidney; 
Reabsorption and efflux 
Liver: 
Metabolism, distribution 
Brain 
Influx/Efflux across the BBB 
GI; 
Absorption and efflux 
Bovine endothelial cells 
 
Intestinal cells, Caco-2 
 
Kidney tubule cells 
LLC-PK1, SKPT, MDCK 
Lung: 
Absorption, metabolism. 
Calu-3 cells. 
   
 
 
   
  
  
  
 
 
   
   
 
  
 
  
  
  
    
 
 
    
  
   
 
   
    
   
   
Localisation of PEPT1 
PEPT1 
Adapted from  http://www.colorado.edu and www.meb.uni-bonn.de/cancer.gov 
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The PEPT1 protein 
 
 hPEPT1 is expressed in the small intestine, 
pancreas, kidney and liver 
 
 Consist of 708 amino acids, ~79 kDa   
 
 Predicted to contain 12 transmembrane 
domains 
 
 Proton coupled and electrogenic 
 
 Ancestral forms dates back to prokaryotes 
 
Fei et al. 1994 
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The di/tri-peptide transport pathway 
Adapted from Nielsen,M.J.  2006 
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Human peptide transporter 1 
(hPEPT1) substrates 
 
 
 
Di-and tripeptides (~8400 combinations) 
β-lactam antibiotics (aminopenicillins and 
cephalosporins) 
Bestatin (anticancer drug) 
Valaciclovir (transport form of Aciclovir) 
 
Both acidic, neutral and basic peptides are 
transported 
 
The transport system has a preference for 
L-amino acids 
Dias 6 
Examples of Drugs taken up via hPEPT1 
Substance Structure Ki (mM) Bioavailability 
Acyclovir Not a 
substrate 
15 % 
Valacyclovir 0,7 54 % 
Ceftibuten 0,3 80 % 
Enalapril  4,6 60 % 
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Ref.: Bretschneider et al. 1999, Ganapathy et al. 1998, Herrera-Ruiz et al. 2004 and Micromedex  
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hPepT1 is a high capacity 
“promiscous” transporter 
 
   
 
 
   
  
  
  
 
 
   
   
 
  
 
  
  
  
    
 
 
    
  
   
 
   
    
   
   
The hPEPT1 drug delivery project 
Aim: To investigate the potential of hPEPT1-
mediated transport as a drug delivery route for 
peptidomimetics or peptidomimetic prodrugs. 
 
Initial strategy: To make a structure-affinity 
relationship of ligands binding to hPEPT1, in 
order to be able to identify molecular features 
in the substrate, necessary for binding. 
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The hPEPT1 prodrug concept 
NH3+
N
O
O
O
R1 
R2 
C-terminal 
Dias 10 
Stable backbone 
(pro-moiety) 
Linker/bond 
Drug Initial studies: Backbone configurations 
Linker stability 
Model drug size 
Focus on R1 
 
   
 
 
   
  
  
  
 
 
   
   
 
  
 
  
  
  
    
 
 
    
  
   
 
   
    
   
   
The assay system, the Caco-2  
intestinal cell culture model 
 Grows on permeable membranes for 
21 days in 95%O2/5%CO2 . 
 
 Media contains salts, serum, L-
glutamine , NEEA & Pen/Strep. 
 
 Growth is dependent on passage 
number, serum batches and 
technician. 
 
 Monolayer transport characteristics 
must be characterized routinely by 
measuring TEER, mannitol fluxes and 
standard substrates, along with CLSM 
imaging of morphology. 
 
Caco-2 cells express hPEPT1 n the 
apical membrane after 21 days of 
culture 
http://inn.ingrm.it/Ricerca/transport/Heavymetal.htm 
Dias 11 Nielsen et al, 2001 
hPEPT1 localization 
   
 
 
   
  
  
  
 
 
   
   
 
  
 
  
  
  
    
 
 
    
  
   
 
   
    
   
   
The assay system, hPepT1  activity and substrate 
affinity is measured using radiolabelled stable 
dipeptide 
Structure-activity relationships 
were made by competition assays 
estimating inhibition constants (Ki) 
against a known stable  
radiolabelled substrate,  
glycylsarcosine (14C-Gly-Sar) 
 
Radiolabelled stable peptide 
i.e. Gly-Sar 
competing substrate 
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N
O
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N
OH
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CH3
O
O
CH3NH
Glu(Acyclothymidine)-Sar, 
 a promising model pro-drug?. 
 
Ki 0.072±0.002mM  
(natural substrates have Ki's 
below 2mM) 
 
Stable backbone 
(methylated) 
 
t½ at pH 7.4 is 3.7 hours 
(drug release) 
 
Translocation ? 
Erikson et al, Eur J Pharm Sci 2005 25, 145-154 
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Translocation can be tested by measuring pHi 
Adapted from Nielsen,M.J.  2006 
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a) buffer pH = 7.4,  
b) buffer pH 6.0,  
1) 2 mM Gly-Sar in buffer pH 6.0  
2) 0.23 mM III (Glu(Acyclothymidine)-Sar).  
Addition of substrate causes 
intracellular acidification 
Erikson et al, Eur J Pharm Sci 2005 25, 145-154 
Dias 15 
Ussing-chamber on 
microscope stage 
BCECF for pHi 
measurements 
   
 
 
   
  
  
  
 
 
   
   
 
  
 
  
  
  
    
 
 
    
  
   
 
   
    
   
   
Failure; Affinity does not necessarily imply translocation 
Derivatisation in the R1 position led to a number of inhibitors 
of PEPT1-mediated substrate uptake 
 
In order to predict uptake via PEPT1, translocation must be 
measured (in-silico models has previously primarily been 
based on competition studies) 
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New strategy in the hPEPT1 drug delivery project 
Aim: To investigate the potential of hPEPT1-mediated transport 
as a drug delivery route for peptidomimetics or 
peptidomimetic prodrugs. 
 
Revised strategy: To make a structure-translocation affinity 
relationsship of lsubstrates transported by hPEPT1, in order 
to be able to identify molecular features in the substrate, 
necessary for binding and subsequent translocation. 
 
 
Revised goal: To obtain a predictive computational model for 
hPEPT1-substrates. 
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PEPT1 substrate translocation estimated via 
intracellular acidification or changes in membrane 
potential 
H+ +H3N
H
N
CH3
O
COO-
CH3
δ+  
Translocation is 
accompanied by 
acidification 
Translocation is 
accompanied by 
depolarisation 
H+ 
- one charge per substrate - coupling ratio varies  
with charge of substrate 
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Assay: A membrane potential 
assay and plate reader setup  
was employed 
+ + + + + + + +    
- - - - - - - - - - -   + - + - + - + - + -  
 - + - + - + - + - + 
Extracellular 
Intracellular 
Ex: 544 nm 
Em: 590 nm 
Lipofilic, anionic, bis-oxonol 
dye. 
FLIPR membrane potential 
assay 
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Assay:  MDCK-hPEPT1 cells 
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Dias 20 
Kindly donated from Bristol-Meyers 
Squibb Company  
MDCK-hPEPT1 cells 
were grown under 
standard conditions 
for 3 days 
14C-Gly-Sar 
   
 
 
   
  
  
  
 
 
   
   
 
  
 
  
  
  
    
 
 
    
  
   
 
   
    
   
   
Translocation of substrates can be measured directly 
Gly-Sar
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Test set 
• 55 di- and tripeptides was selected, using 
computational methods (PCA, VolSurf descriptors). 
 
• The compounds were been tested for their 
translocation properties (Km,Vmax).  
 
• A structure-translocation relationship was constructed 
(QSAR, tested against a randomly choosen test set). 
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Hydrophilic interactions in the side chains lowered 
lumen-cell translocation rate 
Dias 23 
Enhedens navn 
Omkvist et al, 2010. 
Met-Pro-Pro inhibitor: Ki=20 um 
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 Recent examples of prodrugs designed for carrier-mediated transport via hPEPT1. 
 
Parent drug Structure Promoiety (R) hPEPT1 affinity Comparison of prodrug versus parent drug  Reference 
[3-
(hydroxymethyl)- 
phenyl]guanidine 
(3-HPG) 
 
Val 
Ile 0.65 (IC50, mM)
a
 
0.63 (IC50, mM)
a Both prodrugs showed increased permeability as compared to the parent drug in an in situ rat perfusion study Sun et al., 2010 [81] 
Zanamivir 
 
Val 1.19 (IC
50
, mM)
a The valyl ester prodrug showed increased permeability in both cellular transport studies in Caco-2 cells and in in situ rat 
perfusion studies as compared to the parent drug.  Gupta et al., 2011 [82] 
Guanidin 
oseltamivir 
carboxylate 
(GOC) 
 
Val 0.19 (IC
50
, mM)
a The ester prodrug showed increased cellular uptake, rat intestinal permeability and bioavailability in mice when 
compared to the parent drug Gupta et al., 2013 [83] 
Didanosine 
 
Val 0.27 (IC
50
, mM)
a Oral bioavailability in rats was increased from 8 % for the parent drug to 47 % for the valyl ester prodrug  Yan et al., 2011 [84] 
Maltosine 
 Ala-R 
R-Ala 0.33 (Ki, mM)
a 
0.16 (K
i
, mM)
a 
Electrophysiological measurements in hPEPT1-expressing 
oocytes showed significant  increase in transport of the 
prodrugs as compared to maltosine Geissler et al., 2011 [89] 
Rebamipide 
 
Ser-Gly ND 
Electrophysiological measurements in hPEPT1-expressing 
oocytes, cellular transport studies in Caco-2 cells and intestinal 
in situ rat perfusion experiments showed increased transport of 
the dipeptide ester prodrug as compared to rebamipide.  
Kikuchi et al., 2009 [91] 
Thiodipeptide 
conjugate of 
nabumetone 
 
- 0.46 (Ki, mM)b 
Cellular transport studies in Caco-2 cells showed increased 
permeability of the prodrug when compared to the known 
hPEPT1 substrate  
PheΨ[CS-NH]-Ala  
Foley et al., 2009 [92] 
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a) In competition with Gly-Sar 
b) In competition with D-Phe-Gln 
Saaby et al, 2013. 
The hPEPT1 prodrug concept 
NH3+
N
O
O
O
R1 
R2 
C-terminal 
Dias 25 
Stable backbone 
(pro-moiety) 
Linker/bond 
Drug Backbone configurations Linker stability 
Model drug size 
R1 not ideal 
 
Challenges and future directions 
Expansion of substrate sets to include more 
diverse compounds 
 
Crystal structure of hPEPT1 for understanding of 
binding and translocation pocket 
 
True ”rational” design not possible yet 
 
Characterisation of the basolateral peptide 
transport exit step remains. 
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Sted og dato 
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Thank you for your attention.  
   
 
 
   
  
  
  
 
 
   
   
 
  
 
  
  
  
    
 
 
    
  
   
 
   
    
   
   
Supplementary slides 
Sted og dato 
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Intestinal cells, Caco-2 
Apical side, “lumen” 
Basolateral side, “blood” 
HBSS 
HBSS 
We measure fluxes and kinetics of drug transport in 
barrier tissues 
Flux 
Kinetics 
][
][max
SK
SJJ
m
o +
=
Absorption of peptides from the small intestine 
 Proteins are broken down 
to peptides and amino acids in the 
stomach and in the small intestine. 
  Three hours after a protein 
meal (50 g bovine serum albumine), 
120 mM of amino acids in the small 
intestine are in the form of peptides 
(with the majority consisting of 2-4 
peptides), 30 mM are in the form of 
free amino acids 
 Peptide transport probably 
accounts  for  ~50 % of total amino 
acid uptake 
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Molecular characteristics of human 
 di/tri-peptide transporters 
 
Transporter hPepT1 hPepT1-RF* hPepT2 
 
 
Family POT POT POT  
Accession No. U13173 AB001328 PS01023 
g2833279 
 
Chromos. loc. 13q.34-q.35  3q13.3-q21  
Protein length 708 a.a. 208 a.a. 729 a.a.  
TMD’s 12  12  
Substrate oligopeptides 
peptoid drugs 
- oligopeptides 
peptoid drugs 
 
Tissue distrib. intestines intestines Kidney, brain(?)  
Function H+-dependent 
transport 
pH-sensing 
regulatory 
factor  
H+-dependent 
transport 
 
*Possible alternative splicing product of hPepT1 
 Expression is however questionable (Sondergaard et al, 2013) 
4 
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1 
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Proposed model for substrate binding to hPEPT1 
The backbone of a substrate must 
mimick a di- or a tripeptide.  
 
Properties of the side chains (R1 
and R2) influences binding 
1) Ionic interaction 
2) Hydrogen bonding 
3) Interaction with histidine 
residue 
4) Hydrophobic pocket 
Bailey et al. Angew. Chem. Int. Ed.  
39:505-508, 2000 
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Di-and tripeptides as substrates 
• The peptide transporter accepts di- and tripeptides 
(400 + 8000 possible combinations) 
 
• Both acidic, neutral and basic peptides are 
transported 
 
• The transport system has a preference for L-amino 
acids 
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Allowed backbone conformations 
Steffansen et al., 2005 EJPB 
60, 241-245 Andersen 2006 
Regular peptide bond         + 
L/D peptide                       + 
Ketomethylene                  + 
N-methyl amide                 + 
Methylene amino                - 
Hydroxyethylidene              - 
Thio amide                         + 
Fluoroalkane                       + 
O
N
H
O
N
O
N
H
OH
N
H
S
F F
+ Affinity to PEPT 
- No affinity to PEPT 
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Transporters in GI drug absorption 
Absorptive nutrient transporters 
Amino acids 
Glucose 
Di/tri-peptides 
Organic ions 
 
 
 
 
 
Efflux transporters 
Organic ions 
Hydrophobic xenobiotics 
Adapted from ”Animal Physiology” 
Eckert,Randall & Augustine 1988 
